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Resumen
Objetivo:  Evaluar  la  biocompatibilidad  cutánea  de  un  gel  palpebral  hidratante  nocturno,  y
los posibles  efectos  sobre  la  superficie  ocular  en  los  usuarios  de  lentillas  (UL)  y no  usuarios  de
lentillas  (NUL).  La  fórmula  está  registrada  como  material  médico  de  Tridocosahexaenoina-AOX®
(TDHA-AOX)  (un  triglicérido  de  DHA  concentrado),  con  contenido  de  ácido  hialurónico  (AH).
Párpados;
Disfunción  de  la
superficie  ocular
Métodos:  Se  realizó  un  ensayo  clínico  prospectivo,  aleatorio,  y  oculto  en  62  participantes  de
ambos sexos,  de  edades  comprendidas  entre  20  y  70  an˜os,  distribuidos  como:  (1)  UL  (n  =  30)
Abbreviations: DHA, docosahexaenoic acid; HA, hyaluronic acid; CL, contact lenses; CLU, contact lens users; NCLU, non contact lens
users; OS, ocular surface; OSDI, ocular surface disease index; DEs, dry eye syndrome; CLDEQ, contact lens dry eye questionnaire; FBUT,
fluorescein break-up time; VEGF, vascular endothelial growth factor; DE, dry eye; ALA, alpha linolenic acid; EPA, eicosapentaenoic acid;
LC PUFAs, long chain polyunsaturated fatty acids; BCVA, best corrected visual acuity; BMC, biomicroscopy; TDAH-AOX, tridocosahexaenoin-
antioxidant; IOP, intraocular pressure; RE, right eye; LE, left eye.Please  cite  this  article  in  press  as:  Pinazo-Durán  MD,  et  al.  Efficacy  and  safety  study  of  an  eyelid
gel  after  repeated  nocturnal  application  in  healthy  contact  lens  users  and  non-users.  J  Optom.  (2020),
https://doi.org/10.1016/j.optom.2019.12.002
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y  (2)  NUL  (n  =  32).  A  todos  los  participantes  se  les  indicó  la  aplicación  de  una  dosis  única  de
gel hidratante  (con  contenido  de  TDHA-AOX  y  AH)  por  la  noche  en  los  párpados  superior  e
inferior del  ojo  derecho  (OD)  únicamente,  durante  2  semanas  consecutivas.  Se  realizaron  entre-
vistas personales,  cuestionarios,  exámenes  oftálmicos  y  recolección  de  lágrimas  reflejas.  Los
parámetros  oftalmológicos  incluyeron  respuesta  de  la  superficie  ocular  y  estatus  de  las  lentillas.
También  se  registraron  los  niveles  de  satisfacción/episodios  adversos.  Los  parámetros  bioquími-
cos incluyeron  la  determinación  basal  y  final  de  las  moléculas  del  mediador  pro-inflamatorio  en
muestras de  lágrimas  mediante  análisis  multiplex.  Las  estadísticas  se  realizaron  con  el  programa
SPSS 24.0.
Resultados:  El  grupo  UL  reflejó  una  disfunción  mayor  en  OS  que  el  grupo  NUL,  pero  los  parámet-
ros clínicos  generales  (tinción  de  la  córnea,  y  pruebas  Schirmer/FBUT)  y  puntuaciones  OSDI
mostraron una  mejora  significativa  en  los  individuos  UL  en  comparación  con  los  participantes
NUL, al  finalizar  el  estudio.  Las  puntuaciones  CLDEQ-8  sen˜alaron  una  mejora  significativa  del
riesgo inicial  de  desarrollar  sequedad  ocular  aplicando  el  gel  palpebral.  Con  los  análisis  multi-
plex se  identificaron  una  serie  de  citocinas/quimiocinas  en  las  lágrimas  de  los  participantes.  Se
encontró una  expresión  notablemente  superior  de  interleucinas  -1,  -6,  -10,  factor  de  necro-
sis tumoral,  y  VEGF  en  las  lágrimas  de  los  ojos  UL  con  respecto  a  NUL.  Dichas  moléculas
mostraron  una  tendencia  a  disminuir  en  el  OD  de  los  sujetos  UL,  tras  la  aplicación  nocturna
del gel  palpebral.
Conclusiones:  El  gel  palpebral  aportó  hidratación  y  descongestión  cutáneas  seguras  y  eficientes,
y una  mejora  de  la  superficie  ocular  durante  el  suen˜o.
© 2020  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Abstract
Purpose:  To  evaluate  skin  biocompatibility  of  a  nighttime  hydrating  eyelid  gel  and  possible
ocular surface  effects  in  contact  lens  users  (CLU)  and  non-contact  lens  users  (NCLU).  The
formulation  is  registered  as  a  medical  device  as  Tridocosahexaenoine-AOX® (TDHA-AOX)  (a
concentrated  DHA  triglyceride),  containing  also  hyaluronic  acid  (HA).
Methods:  A  prospective,  randomized,  masked  clinical  trial  was  performed  with  62  participants
of both  sexes,  aged  20--70  years,  split  into:  (1)  CLU  (n  =  30)  and  (2)  NCLU  (n  =  32).  All  participants
were instructed  to  apply  a  single  dose  of  the  moisturizing  gel  (containing  TDHA-AOX  and  HA)
nightly to  the  upper  and  inner  eyelids  of  their  right  eye  (RE)  only,  and  during  2  consecutive
weeks. Personal  interviews,  questionnaires,  ophthalmic  examinations  and  reflex  tear  collection
were performed.  Ophthalmological  parameters  included  ocular  surface  response  and  contact
lens status.  Levels  of  satisfaction/adverse  events  were  also  recorded.  Biochemical  parameters
included  basal  and  final  determination  of  pro-inflammatory  mediator  molecules  in  tear  samples
by multiplex  analyses.  Statistics  were  done  by  the  SPSS  24.0  program.
Results:  The  CLU  group  had  higher  OS  dysfunction  than  NCLU,  but  overall  clinical  parameters
(corneal staining,  and  Schirmer/FBUT  tests)  and  OSDI  scores  showed  significant  improvement
in CLU  individuals  as  compared  to  the  NCLU  participants,  at  the  end  of  study.  CLDEQ-8  scores
pinpointed  significant  amelioration  in  initial  risk  of  developing  DEs  by  applying  eyelid  gel.  Multi-
plex analyses  demonstrated  significantly  lower  VEGF  expression  levels  (p  <  0,05)  in  tears  among
the CLU  compared  to  NCLU  after  nightly  application  of  eyelid  gel.
Conclusions:  Eyelid  gel  appeared  to  safely  and  efficiently  provide  hydration  and  decongestion
of the  skin  and  amelioration  of  the  ocular  surface  during  sleep.
© 2020  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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ry  eyes  (DEs)  result  from  a  wide  variety  of  changes
ccurring  in  one  or  more  ocular  surface  (OS)  components.
cular  discomfort  and  visual  disability  occurs  in  varying
o
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Oegrees  through  the  disease.1,2According  to  etiology  and
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Efficacy  and  safety  study  of  an  eyelid  gel  after  repeated  noc
A  search  of  the  scientific  literature  has  shown  scarce
reports  on  the  statistics  regarding  the  contact  lenses  (CL)
users  (CLU)  in  the  most  recent  years,  in  Spain.  Santodomingo
et  al.,6 published  that  in  2017  the  number  of  neophyte
CLU  was  up  to  700,  whereas  these  data  were  about  19000
new  CLU  in  other  29  countries.  In  2019,  a  country  report
on  the  contact  lenses  and  solutions  in  Spain  https://www.
euromonitor.com/contact-lenses-and-solutions-in-spain/
report)  concluded  that  an  increased  decision  of  CL  instead  of
wearing  glasses  are  occurring  in  the  most  active  Spaniards,
throughout  the  last  years.
Among  CL  users  (CLU),  eye  diseases  affecting  lubrica-
tion,  usually  involving  tear  production  impairment,  corneal
surface  disorders,  conjunctival  as  well  as  palpebral  gland
dysfunction,  are  most  frequent.7 Most  CL-associated  DEs
manifestations  have  been  managed  by  prescribing  artifi-
cial  tears  during  the  day,  and  lubricant  gels/creams  at
night,  often  with  unsatisfactory  results.  But,  according  to
Ablamowicz  and  Nichols,8 this  is  not  the  first-line  recom-
mendation,  but  changing  to  a  CL  with  a  more  periodic
replacement  schedule.  The  main  goal  is  to  reach  the  biggest
success  for  CLs  continuation,  by  better  understanding  the
causes  of  signs  and  symptoms  of  OS  dysfunction.
The  major  etiopathogenic  mechanism  for  CL-associated
DEs  is  the  lack  of  tear  film  stability,  leading  to  lipid  layer
reduction,  subsequent  increase  in  aqueous  layer  evapora-
tion  and  noticeable  hyperosmolarity.7--9 To  counteract  these
disorders,  it  has  been  shown  that  over-the-counter  use
of  unpreserved  artificial  tears,  eye  gels  and  lubricants9,10
and  phospholipid-liposome  eye  spray,11 as  well  as  a  com-
bination  of  these,  yields  optimum  results  in  the  affected
individuals.7--11 Furthermore,  up  to  two-thirds  of  CLU  make
use  of  cleaning  and  disinfecting  products  that  include  chem-
icals  (antimicrobial  agents,  preservatives,  buffer  systems,
and  surfactants)  that  can  interfere  with  the  integrity  and
function  of  the  anterior  eye  and  adnexa  structures,  resul-
ting  in  a  wide  range  of  clinical  manifestations.  Recent
reports  have  also  confirmed  the  negative  effects  of  these
products  (e.g.,  EDTA,  polyhexanide,  boric  acid,  hydrogen
peroxide,  poloxamer)  on  the  tear  film,  corneal  surface  and
conjunctiva.12
New  strategies  for  preventing  and  treating  DEs  have
therefore  been  proposed.  The  dietary  precursor  linolenic
acid  (ALA,  C18:3)  synthesizes  eicosapentaenoic  acid  (EPA;
C20:5  3)  and  docosahexaenoic  acid  (DHA;  C22:6  3),  the
two  major  omega-3  (-3)  long-chain  polyunsaturated  fatty
acids  (LC-PUFAs)  essential  for  humans.  These  play  fun-
damental  roles  in  the  regulation  of  OS  morphology  and
function.13 A  wide  spectrum  of  reports  have  demonstrated
that  -3  LC-PUFAs  either  from  food  or  oral  food  supple-
ments  induce  positive  responses  on  global  health,14 as  well
as  in  several  diseases,  including  DEs.5,15--18 Indeed,  LC-  -3
fatty  acids  are  incorporated  into  the  cell  membrane  phos-
pholipids.  Tridocosahexaenoine-AOX® (TDAH-AOX)  is  a  highly
concentrated  DHA  triglyceride,  patented  as  a  biological
molecule  that  offers  both  cellular  antioxidant  protection
and  anti-inflammatory  activity19--21 by  (1)  stimulating  the
intracytoplasmic  synthesis  of  glutathione;  (2)  inhibiting  E2Please  cite  this  article  in  press  as:  Pinaz
study  of  an  eyelid  gel  after  repeated  
lens  users  and  non-users.  J  Optom.  (
proinflammatory  prostaglandins  synthesis,  but  stimulating
the  anti-inflammatory  E3  prostaglandins  synthesis;  and  (3)
favoring  the  resolution  process  of  inflammation  by  inducing
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esolvins  and  protectins.
Nevertheless,  it  would  be  useful  to  prepare  a  pre-
iminary  personalized  approach  based  on  the  risk-benefit
ssessment  for  CLU  and  NCLU.  Indeed,  effectiveness,  side
ffects/safety,  and  route  of  administration  are  the  usual
onsiderations  when  addressing  new  treatments,  especially
or  OS.  We  therefore  performed  a  biocompatibility  assess-
ent  and  recommended  indications  of  daily  nocturnal
dministration  of  an  eyelid  gel  containing  TDHA-AOX  for  OS
n  CL,  to  give  new  practical  advice  in  addressing  DEs  in  CLU.
aterial and methods
he  present  work  adheres  to  the  Ethical  Principles  for
edical  Research  involving  human  subjects  [Declaration  of
elsinki  (Edinburgh,  2000)],  and  the  Ethics  Committee  stan-
ards  of  the  study  centers  (no.  1017/2016-2017).
tudy  design
 prospective,  randomized,  interventional,  multicenter,
asked  clinical  trial  was  conducted  between  2017/2018.
The  main  goal  of  the  present  study  was  to  evaluate  the
fficacy  and  safety  of  the  nightly  application  on  the  right
pper  and  inner  eyelids,  of  a  gel-cream  containing  TDHA-
OX,  over  15  consecutive  days.  The  left  eye  was  used  as
he  control.  The  evaluation  criteria  will  lay  over  the  skin
eatures,  as  well  as  over  the  OS  clinical  parameters.
The  secondary  endpoint  was  to  look  at  the  effects  of  the
bove  gel  formulation  on  tear  levels  of  pro-inflammatory
ediators  by  multiplex  analyses.
The  sample  size  for  this  preliminary  study  was  calculated
y  the  eNe  3.0  (GlaxoSmithKline  S.A.)  statistical  program,
n  order  to  reach  an  statistical  power  of  80  % that  permit  to
etect  differences  in  hypotheses  contrast  (Ho:  p1  =  p2)  by
eans  of  the  2 bilateral  for  2  independent  samples,  with  a
ignificance  level  of  5%.
atients
nitial  eligibility  interviews  were  conducted  with  72  poten-
ial  candidates  of  both  sexes  (144  eyes),  aged  22--60  years,
uring  the  ordinary  ophthalmologic  appointments  in  the
tudy  centers,  according  to  the  study  inclusion/exclusion
riteria,  as  listed  in  the  Table  1. 68  participants  were  initially
ncluded,  extensively  informed  about  the  study  characteris-
ics  and  provided  written  informed  consent.  Subjects  were
lassified  into  2  groups:  (1)  contact  lens  users,  CLU  (n  =  34)
nd  (2)  non-contact  lens  users  NCLU  (n  =  34).
perative  procedures
nterview  and  recruitment
he  following  baseline  interview  data  were  recorded:  socio-
emographic  information,  personal/familial  background,o-Durán  MD,  et  al.  Efficacy  and  safety
nocturnal  application  in  healthy  contact
2020),  https://doi.org/10.1016/j.optom.2019.12.002
ifestyle  characteristics,  and  global  ophthalmological  and
ystemic  aspects.  At  baseline,  all  participants  underwent  a
recise  ophthalmological  examination  in  both  eyes,  includ-
ng  best-corrected  visual  acuity  (BCVA);  intraocular  pressure
ARTICLE IN PRESS+ModelOPTOM-316; No. of Pages 10
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Table  1  Inclusion  and  exclusion  criteria  for  the  study  participants.
INCLUSION  CRITERIA  EXCLUSION  CRITERIA
• Both  sexes
•  aged  22--60  years
• Clinical  evaluation  of  the  Ocular  Surface:
- None-to-Mild  dry  eye  symptoms:  itchiness,
photophobia,  burning,  stinging,  grittiness,  tired  eyes,
redness,  blurred  vision.
- OSDI  <13
-  BUT  >10
-  No  Corneal/Conjunctival  staining
• Positive  aptitude  to  participate  in  the  study
• Informed  consent  to  participate  in  the  study
Relevant  organic  ocular  or  systemic  disorder  and
treatment.
History  of  genetic  disease
Topical  and/or  systemic  allergy  or  hipersensitivity  to  the
substances  used  in  the  study.
Moderate-to-severe  refractive  error.
Clinical  evaluation  of  the  Ocular  Surface:
Moderate-to-Severe  dry  eye  signs  and  symptoms:
grittiness,  foreign  body  sensation,  burning,  stinging,
photophobia,  tearing,  redness,  blurred  vision,  impaired
visual  acuity.
OSDI  >13
BUT  <10
Fluorescein  and  Rose  of  Bengal  positive  staining
Meibomian  Gland  Dysfunction
Corneal  Oedema
Corneal  abrasion
Keratitis
Keratoconus
Previous  Refractive  surgery  (Laser  or  Intraocular  Lens).
History  of  Anterior  Eye  Segment  surgery  (cataracts,
glaucoma,  keratoplasty)
Simultaneous  participation  in  other  study
Unable  to  participate  in  the  study
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eIOP);  and  biomicroscopy  (BMC)  of  the  anterior  eye  segment
nd  adnexa.  Among  the  latter,  the  major  outcome  variables
ere:  eyelid  status,  Schirmer  and  fluorescein  break  up  time
FBUT)  tests,  fluorescein  corneal  staining,  Rose  of  Bengal
taining,  and  presence  of  deposits  on  the  CL  surface.  Other
arameters----including  OS  response  by  means  of  the  clinical
valuation  (as  above  said),  characteristics  and  status,  user
ensations,  as  well  as  adverse  events----were  fully  evaluated
t  baseline,  and  also  at  the  end  of  study.  The  ocular  surface
isorder  index  (OSDI  [Allergan  Inc.,  Irvine,  California,  USA])
uestionnaire  was  carried  out  in  all  participants  to  differen-
iate  those  with  normal,  mild,  moderate,  or  severe  DEs.  The
SDI  includes  12  items  and  each  answer  is  evaluated  from
 to  0  (higher  to  lower);  the  final  OSDI  score  is  the  result
f  applying  the  following  formula:  Sum  of  scores  from  all
uestions  answered  ×  25/Number  of  questions  answered.
he  overall  OSDI  score  delineates  the  OS  from  normal  (0--12
oints),  mild  disorder  (13--22  points),  moderate  disorder
23--32  points),  to  severe  stage  of  disease  (33--100  points).21
he  Contact  Lens  Dry  Eye  Questionnaire  (CLDEQ)  was  set
p  to  measure  dryness  symptoms  among  CLU.22 This  tool
as  originally  designed  in  parallel  to  the  Dry  Eye  Ques-
ionnaire  (DEQ)  for  NCLU  to  decipher  the  prevalence  of
iscomfort,  dryness,  and  blurred  vision  among  CLU.  How-
ver,  the  CLDEQ-8  (a  short  version  of  the  CLDEQ),  the  one
sed  in  the  present  study,  was  developed  to  determine  the
pinion  of  CLU  with  respect  to:  new  lenses,  care  products,Please  cite  this  article  in  press  as:  Pinazo-Durán  MD
gel  after  repeated  nocturnal  application  in  healthy  co
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nd  replacement  schedules,  as  well  as  new  eye  therapies,  as
reviously  reported.23 Participants  with  a  score  higher  than
2  are  progressively  considered  vulnerable  to  developing
Es,  while  those  with  scores  lower  than  12  have  appar-
a
p
u
TNo signed  informed  consent
ntly  no  risk  of  developing  DEs.  In  addition,  a  questionnaire
personally  designed  to  gather  knowledge  on  the  subjective
ensations  of  the  eyelid  skin,  product  appreciation/adverse
ffects)  was  given  to  all  individuals.  Prior  to  the  first
tudy  visit,  participants  were  required  to  discontinue,  for
t  least  1  month,  the  use  of  nutritional  supplements,  sys-
emic  antihistamines,  and  treatments  for  DEs  (or  meibomian
land  disorder)  such  as  eye  cleaning  wipes,  antibiotics,  non-
teroidal  anti-inflammatory  drugs,  and  corticosteroids,  as
ell  as  artificial  tears.  The  study  product  was  a  gel  pro-
ected  from  air  by  an  airless  container,  containing  10  mL  of
el,  that  provides  0.2  mL  per  pulse  (approximately  50  doses
er  container),  which  has  been  previously  tested  for  cos-
etic  use.  The  complete  formula  is  reflected  in  Table  2,  but
ssentially  contains  HA  and  a  patented  DHA  triglyceride
European  Patent  EP  1  962  825  B1  held  by  Brudy  Technol-
gy  SL  related  to  the  use  of  DHA  for  treating  a  pathology
ssociated  with  cellular  oxidative  damage.  European  patent
ranted,  date  April  2,  2014).15--20 The  product  was  manufac-
ured  by  the  pharmaceutical  company  (Brudylab,  Barcelona,
pain)  and  gently  provided  in  unlabeled  individual  plastic
ontainers  (similar  in  size  and  shape  to  the  eyedrop  recep-
acles)  to  the  investigators,  and  the  doctors  gave  them  to
ll  participants  without  any  charge.  Neither  the  investiga-
ors  nor  the  participants  knew  the  specific  composition  of
he  product.  The  information  provided  by  the  manufactur-
rs  included  that  the  study  product  did  not  contain  harmful,  et  al.  Efficacy  and  safety  study  of  an  eyelid
ntact  lens  users  and  non-users.  J  Optom.  (2020),
gents  for  the  skin,  eyes  and  vision  in  the  formulation.  All
articipants  were  instructed  to  apply  the  gel  nightly,  on  the
pper  and  inner  right  eyelids,  to  be  maintained  overnight.
he  procedure  was  as  follows:  the  CLU  previously  removed
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CLU
(n=30)                 
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(n=30) 
End of study participants            
Baseli ne
(n=68)
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(n=34)          
NCLU
(n=34) 
Baseline Participants 
Interview and data recording 
Ophthalmic Examination
Tear Collecting Samples
Interview and data recording 
Ophthalmic Examination
Tear Collecting Samples
EYELID GEL  STU DY
RECRUITED PARTICI PAN TS:  72
Figure  1  Flowchart  of  the  study  participants  and  procedures  perf
CLU: contact  lens  users;  NCLU:  non-contact  lens  users.
Table  2  Complete  formula  of  the  gel-cream  tested.
List  of  ingredients
DHA  concentrated  triglyceride  0,7%
Sodium  hyaluronate  0,2%
Aloe  Vera  3,0%
Propylene  glycol
Glycerine
Avocado  oil
Caprylic/Capric  Triglyceride
Olive  oil
Xanthan  gum
Sesame  oil
Polysorbate  80
Soybean  lecithin
Grapefruit  oil
Sodium  citrate
Sorbitan  monolaurate
Tris(hydroxymethyl)aminomethane
Tocopheryl  acetate
Grape  seed  oil
Hydroxypropyl  methyl  cellulose
Citric  acid  monohydrate
Tea  tree  oil
Geranium  oil
Phenethyl  alcohol
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the  CL,  no  eyedrops  were  instilled,  the  eyelids  have  to  be
free  of  cleansing  lotions,  make-up,  or  beauty  products,  the
participants  have  to  apply  a  small  amount  of  gel  to  the
skin  of  the  right  closed  eyelids,  using  the  fingertip  to  give  a
brief,  soft  massage,  and  not  on  the  left  eyes,  that  will  be
considered  as  the  controls.  Application  just  before  bedtime
was  especially  recommended.  Participants  were  specificallyPlease  cite  this  article  in  press  as:  Pinazo-Durán  MD
gel  after  repeated  nocturnal  application  in  healthy  co
https://doi.org/10.1016/j.optom.2019.12.002
advised  that  this  product  was  for  external  use  on  intact
eyelid  skin  and  should  never  be  applied  to  the  eye.  At  the
starting  point,  73  suitable  participants  were  included  in  the
study  (according  to  the  inclusion/exclusion  criteria,  pre-
(
p
t
pormed.
isely  reflected  in  the  Table  1).  A  summary  of  the  visits  and
rocedures  is  shown  in  Fig.  1.
phthalmologic  examination
 systematized  eye  examination  was  performed  and  all
ata  recorded  in  a  database  specifically  designed  using  the
icrosoft  Excel  program:  best  corrected  visual  acuity  in
ach  eye  (BCVA),  biomicroscopy  of  the  anterior  eye  segment
nd  adnexa  (BMC)  by  the  slit  lamp  (Hagg-Streit  AG,  Koeniz,
witzerland),  to  explore  the  OS  structures  with/without
uorescein  and  rose  of  Bengal  staining;  Schirmer’s  test
ith  anesthesia,  fluorescein  break  up  time  (FBUT),  and  IOP
y  the  aplanation  tonometer  (Haag-Streit  AT-900,  Koeniz,
witzerland)  after  instillation  of  a  single  drop  of  Flu-
test ® (sodic  fluorescein  plus  oxibuprocaine.  Alcon  Cusi,
arcelona,  Spain).  Briefly,  a  standard  Schirmer  test  with
opical  anesthesia  (Anestesico  Doble ® 0.5%  oxibuprocaine
ydrochloride  plus  tetracaine  hydrochloride  eye  drops.
lcon  Cusi,  Barcelona,  Spain)  was  performed.  A  sterilized
lter  paper  strip  (5  mm  ×  35  mm)  was  placed  in  the  exter-
al  canthus  of  the  inferior  eyelid  and  left  in  place  for  5  min.
etting  of  the  paper  after  5  min  was  recorded  in  mm  accord-
ng  to  the  scale  provided.  The  wetting  strips  <10  mm  per
 min  were  diagnosed  positive,  while  ≤5  mm  per  5  min  were
iagnosed  as  strongly  positive.  The  OS  of  both  eyes  was
hen  stained  with  2  L  of  Fluorescein ® (2%  fluorescein  eye
rops,  Alcon  Cusi,  Barcelona,  Spain)  that  were  instilled  into
he  inferior  fornix  of  the  conjunctiva.  The  ophthalmologist
nstructed  participants  to  blink  actively  for  3−5  sec  to  exam-
ne  the  cornea,  conjunctiva,  eyelids  (free  lid  margin  and
uter/inner  eyelid  border),  and  eyelashes.  The  FBUT  was
etermined  as  the  time  period  between  the  last  blink  and
he  apparition  of  a  random  corneal  black  spot  on  the  fluo-
escein  stained  tear  film.  For  each  participant  the  FBUT  was
etermined  three  times  and  the  value  was  expressed  as  the
ean  ±  standard  deviation.  FBUT  was  considered  positive  if
he  final  value  was  less  than  10  sec.  The  rose  of  Bengal  test,  et  al.  Efficacy  and  safety  study  of  an  eyelid
ntact  lens  users  and  non-users.  J  Optom.  (2020),
1%  sodium  rose  of  Bengal  sterile  ophthalmic  strips),  was
erformed  when  applying  one  single  strip  on  the  inferior
arsal  conjunctiva,  and  the  OS  was  examined  by  BMC.  The
ositive  staining  marked  the  damaged  epithelia.  At  the  end
ARTICLE IN+ModelOPTOM-316; No. of Pages 10
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Figure  2  Basal  and  final  OSDI  index  scoring  of  the  total  group
of participating  volunteers  (n  =  60),  and  of  the  separate  groups
of CLU  (n  =  30)  and  NCLU  (n  =  30)  evaluated  after  one  single  night
gel-cream  application  on  the  right  eyelid  skin  over  two  weeks.
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eSDI: Ocular  Surface  Disease  Index;  CLU:  contact  lens  users;
CLU: non-contact  lens  users.
f  the  2-week  period  of  daily  application  of  the  eyelid  gel,
he  participants  underwent  the  same  examination  protocol,
s  performed  in  the  baseline  visit.
ample  collection  and  processing
he  tear  sampling  technique  used  by  our  research  team  has
een  previously  described  elsewhere.5,15--18 During  the  base-
ine  study  visit,  participants  attended  the  ophthalmological
linic  at  9  a.m.  to  undergo  the  above  ophthalmological
xamination.  The  following  day,  reflex  tear  samples  were
xtracted  with  a  capillary  Pasteur  micropipette  from  the
nferior  tear  meniscus  of  the  right  and  left  eyes  separately,
sing  a  gentle  rubbing  softly  technique  (Fig.  2).  Tear  sam-
les  were  then  placed  into  microeppendorfs  (100  L)  and
hese  were  placed  into  cryotubes  that  were  conveniently
abeled  and  stored  in  boxes  at  −80 ◦C  until  processing.  In
ases  of  decreased  tear  production,  the  sampling  proce-
ure  was  repeated  until  an  acceptable  volume  was  obtained
up  to  20--30  L).  Great  care  was  taken  during  tear  sample
onservation  and  manipulation.  Tear  sampling  was  sched-
led  at  baseline  and  at  the  2-week  follow-up  for  biochemical
ssays.  All  experiments  were  performed  in  duplicate  and  the
rotocols  are  described  below.
The  level  of  expression  of  pro-inflammatory  mediators
as  done  by  determining  several  cytokines/chemokines  in
he  tear  samples  by  using  the  Luminex  R-100  multiplex
ystem  (Luminex,  Austin,  TX,  USA).24 The  system  is  able
o  perform  immunodetection  with  a  minimum  amount  of
pproximately  20  L.  The  flow-based  Bio-Plex  suspension
rray  system  (Bio-Rad  Laboratories,  Hercules,  CA,  USA)
as  used  to  identify  and  quantify  each  particular  antigen-
ntibody  reaction.  Identification  of  the  assayed  molecules
as  based  on  bead  color  and  fluorescence,  using  fluorescent-
abeled  reporter  molecules  associated  with  each  target
rotein.  Unknown  cytokine  and  chemokine  concentrations
ere  calculated  automatically  by  the  Bio-Plex  Manager  soft-
are  using  a  standard  curve  derived  from  a  recombinant
ytokine  standard.  Cytokine  and  chemokine  concentrations
ere  corrected  for  the  initial  total  protein  concentration
f  each  human  tear  sample  during  analysis.  The  inflam-Please  cite  this  article  in  press  as:  Pinazo-Durán  MD
gel  after  repeated  nocturnal  application  in  healthy  co
https://doi.org/10.1016/j.optom.2019.12.002
ation  and  immune  response  molecules  analyzed  herein
ere:  interleukin  (IL)-1, IL-2,  IL-4,  IL-5,  IL-6,  IL-8,  IL-
0,  and  IL-12;  vascular  endothelial  growth  factor  (VEGF);
umor  necrosis  factor    (TNF-); granulocyte-macrophage
d
v
p
t PRESS
M.D.  Pinazo-Durán  et  al.
olony-stimulating  factor  (GM-CSF);  and  interferon  .  The
xperiments  were  done  in  duplicate  and  the  results  are
hown  as  the  mean  (SD)  in  pg/mL.
tatistical  analysis
he  Microsoft  Excel  program  and  IBM  Statistical  Package
or  the  Social  Sciences  SPSS  V.24.0  program  (SPSS  Inc.,
hicago,  IL,  USA)  were  used.  For  continuous  variables,
onparametric  (Mann--Whitney  U)  and  parametric  (t  test)
tatistics  were  used,  and  the  results  are  expressed  as
ean  ±  standard  deviation  (SD).  Categorical  variables  are
xpressed  as  percentages.  A  p-value  less  than  0.05  was
onsidered  statistically  significant,  adjusted  by  Bonferroni
orrection  when  pairwise  comparison  in  multiple  groups  was
onducted.
esults
 total  of  60  participants  (30  assigned  to  the  CLU  [33%
ale/67%  female]  and  30  assigned  to  the  NCLU  [30%
ale/70%  female])  completed  the  2-week  follow-up;  120
yes  were  analyzed  both  in  separate,  and  also  as  a  whole
classified  as  pertaining  to  each  of  the  two  study  groups).
ate  of  withdrawal  was  9%.  Lack  of  motivation  and  tear
amples  failing  to  show  any  data  constituted  the  most  com-
on  causes  for  withdrawal.  Mean  age  of  total  participants
as  36  ±  12  years  (32  ±  12  years  in  CLU  and  38  ±  11  years
n  NCLU).  Distribution  by  sex  and  age  was  similar  in  both
roups.
The  CL  status  was  investigated  in  the  corresponding  group
f  the  study  participants  (CLU).  Regarding  the  biomaterials
f  the  CL  utilized  by  our  participants,  100%  corresponded  to
oft  lens  of  silicone  hydrogel  (SiHy),  and  the  frequency  dis-
ribution  according  to  their  distinguishing  properties  was:
2%  were  reusable  spherical  SiHy  CLs  [from  which:  31%
ere  Ultra  mensual  moisture  seal  -samfilcon  A-,  46%  water
ontent  (WC);  and  69%  were  Biofinity  mensual  -comfilcon  A-,
8%  WC],  28%  were  reusable  spherical  SiHY  CLs  (replace-
ent  frequency  two  weeks:  Acuvue  Oasys  -senofilcon  A-,
6%  WC),  and,  finally  20%  of  the  CLs  were  torical  SiHy  CLs
Airoptix  for  astigmatism  -Iotrafilcon  B-,  24%  WC).  Other
hysical  CLs-related  factors,  such  as  thickness/bulk  and/or
dge  configuration  did  not  were  considered  for  the  present
ork.  All  study  participants  utilized  the  CLs  during  the  day-
ime.  Mean  usage  full  time  was:  8,2  ±  3,1  h.
The  OSDI  questionnaire  revealed  that  the  CLU  group
ad  higher  OS  dysfunction  than  the  NCLU  group,  with  a
ignificant  improvement  on  the  overall  scores  among  CLU
ndividuals  for  the  two  study  points  (Fig.  3).
Regarding  CLDEQ-8  scores  obtained  by  the  CLU,  there
ere  differences  between  the  start  and  end  of  study  relating
o  the  application  of  the  eyelid  gel  (regarding  alteration  of
he  OS).  This  means  that  the  participants  improved  their  ini-
ial  risk  of  developing  DEs  by  applying  the  eyelid  gel  (Fig.  4).
The  questionnaire,  designed  by  researchers  to  gather
pinions  on  the  effect  of  the  nightly  application  of  the
yelid-gel  over  2  consecutive  weeks  showed  interesting,  et  al.  Efficacy  and  safety  study  of  an  eyelid
ntact  lens  users  and  non-users.  J  Optom.  (2020),
ata  on  the  positive  participant  appreciation  for  this  inter-
ention,  as  shown  in  the  Table  3. Significantly  higher
ercentages  of  patients  responded  that  the  palpebral  skin  of
he  RE  had  greater  brightness/smoothness  and  more  elastic-
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Figure  3  Basal  and  final  OSDI  index  scoring  of  the  total  group  of  participating  volunteers  (n  =  60),  and  of  the  separate  groups  of
CLU (n  =  30)  and  NCLU  (n  =  30)  evaluated  after  one  single  night  gel-cream  application  on  the  right  eyelid  skin  during  two  weeks.
OSDI: Ocular  Surface  Disease  Index;  CLU:  contact  lens  users;  NCLU:  non-contact  lens  users.
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Figure  4  Basal  and  Final  CLDEQ-8  scoring  evaluating  the  risk  of  developing  dry  eye  (Scoring  >12)  in  the  right  and  left  eyes  of  the
CLU (n  =  30)  after  one  single  night  gel-cream  application  on  the  righ
CLDEQ-8:  Contact  Lens  Dry  Eye  Questionnaire-8;  CLU:  contact  lens  u
Table  3  Results  of  the  Cosmetic  Survey  including  the  opin-
ion of  all  the  participating  volunteers  (n  =  60)  relating  to
the cosmetic  properties  and  possible  detected  skin  adverse
effects,  evaluated  after  one  single  night  gel-cream  applica-
tion on  the  right  eyelid  skin  during  two  weeks.
Cosmetic  test  results  Worsened  Equal  Improved
Skin  brightness  0%  36%  64%
Skin softness  0%  14%  86%
Skin elasticity  0%  27%  73%
Skin Hydration  0%  30%  70%
Skin asverse  effect 0%  0%  0%
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application  in  the  RE  but  not  in  the  LE).  Only  the  VEGFSkin wrinkles  0%  46%  54%
ity/hydration,  as  well  as  amelioration  of  wrinkles  than  the
LE  at  the  end  of  the  study.  No  adverse  effects  were  suffered
or  declared  by  any  participant.
No  changes  in  the  BCVA  and  IOP  values  between  groups
were  observed  between  the  two  study  points.  The  clinical
probes  to  address  the  OS  status,  as  described  before  (Mate-
rial  and  Methods  section)  were  performed  to  all  participants
at  baseline  and  at  the  end  of  study.  In  fact,  descriptive
statistics  for  5 min  wetted  lengths  (mm)  of  Schirmer  stripsPlease  cite  this  article  in  press  as:  Pinazo-Durán  MD
gel  after  repeated  nocturnal  application  in  healthy  co
https://doi.org/10.1016/j.optom.2019.12.002
reflected  that  up  to  18%  of  both  examined  eyes  from  the
CLU  participants  and  9%  of  the  NCLU  eyes  showed  test  read-
ing  <5  mm.  Average  Schirmer  test  value  was  of  8.8  ±  2.6  mm
e
f
et  eyelid  skin  during  two  weeks.
sers.
n  the  CLU  eyes,  versus  13.6  ±  2.3  mm  in  the  NCLU  eyes;
 <  0.05).  Average  TBUT  scores  displayed  no  statistically  sig-
ificant  differences  between  groups  (4.8  ±  1.6  sec  in  the  CLU
yes  versus  6.8  ±  1.5  sec  in  the  NCLU  eyes).  However  at  the
nd  of  follow-up,  a significant  improvement  respect  to  base-
ine  values  was  noticed  in  the  probes  from  the  RE  of  the  CLU
articipants  (Schirmer  test:  13.2  ±  2.2  mm,  p  <  0.05;  TBUT:
.8  ±  1.2  sec,  p  <  0.001)  that  were  similar  to  the  baseline
alues  of  the  RE  from  the  NCLU.  The  biomicroscopy  exami-
ation  showed  no  significant  fluorescein  corneal  staining  and
o  significant  CL  additional  deposits  in  any  case  at  the  end
f  study  (applicable  to  the  eyelid  gel  administration).
Data  from  the  biochemical  analyses  were  quite  sur-
rising.  Up  to  86%  of  the  molecules  of  the  human
ytokine/chemokine  panel  were  detected  in  tears  of  the
tudy  participants  in  the  picomolar  range.  Moreover,  notice-
ble  higher  expression  of  IL1,  IL6,  VEGF  and  TNFa  were
etected  in  the  CLU  as  compared  to  the  NCLU,  at  base-
ine.  However,  it  was  not  fully  demonstrated  changes  in  the
xpression  pattern  of  cytokines/chemokines  in  tears  from
he  two  study  groups  at  the  end  of  study  (regarding  the
L  wearing).  It  was  not  detected  statistically  significant
hanges  in  cytokines/chemokines  tear  expression  between
he  RE  and  LE  of  the  participants  (regarding  the  eyelid-gel,  et  al.  Efficacy  and  safety  study  of  an  eyelid
ntact  lens  users  and  non-users.  J  Optom.  (2020),
xpression  was  noticeably  lower  in  tears  from  the  CLU  group
rom  baseline  (RE:  1200  pg/mL;  LE:  550  pg/mL)  and  at  the
nd  of  study  (RE:  800  pg/mL;  LE:  460  pg/mL).
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Overall,  our  data  demonstrated  a  final  risk  reduction  (2
eeks  from  baseline)  among  CLU  after  nightly  eyelid  gel
pplications.  Improvement  was  detected  when  comparing
nal  vs.  initial  symptom  scores  and  clinical  signs  among
tudy  participants.  Final  scores  were  noticeably  lower  than
he  initial  ones,  pointing  to  a  decrease  in  sensations  and
igns  of  DEs  in  relation  to  OS  changes  induced  by  the  appli-
ation  of  the  eyelid  gel.  The  present  work  with  the  palpebral
ream  received  high  scores  for  comfort  and  personal  positive
ensations  at  day  15.  The  parameters  revealed  noticeable
ifferences  between  the  RE  and  LE.
iscussion
e  evaluated  the  effects  of  nightly  application  in  the  RE  of
n  eyelid  gel  containing  TDHA-AOX  and  HA  on  the  OS  in  CLU
nd  NCLU,  taking  into  consideration  the  contralateral  eye
s  the  control.  At  2-week  follow-up,  we  found  a  significant
ncrease  in  the  Schirmer  and  FBUT  tests  in  RE  assigned  to
he  cream  application  compared  to  the  contralateral  eyes
hat  were  considered  as  the  controls.  Moreover,  noticeably
ower  cytokine/chemokine  expression  was  seen  in  the  tears
f  the  NCLU  group  than  in  the  CLU,  but  the  results  showed
 lack  of  statistical  significance.  In  addition,  it  was  evi-
ent  that  the  gel-treated  eyes  displayed  a  trend  to  diminish
he  cytokine/chemokine  values  as  compared  to  the  non-
reated  eyes,  at  the  end  of  follow-up,  without  statistical
ignificance.  Our  data  also  indicate  that  overnight  external
xposure  to  this  formula  noticeably  improved  the  palpebral
kin  with  an  important  repercussion  on  the  OS  integrity  in
LU  individuals,  based  on  the  presence  of  DHA  in  triglyceride
orm  (DHA-TG).
Chalmers  et  al.,  reported  a  prevalence  of  DE  signs  and
ymptoms  of  about  50%  in  CLU,  twice  the  percentages
eported  by  NCLU  of  similar  age.23 It  has  been  widely
tated  that  wearing  CL  is  one  of  the  most  frequent  external
auses  of  DEs.1--6,8,25,26·  In  our  study,  the  CL  type,  bioma-
erial  properties,  wearing/replacement  schedule  and  eye
are  was  quite  similar  between  the  participants.  In  our
pinion,  when  the  summed  CLDEQ-8  scores  were  obtained
rom  the  study  participants,  an  excellent  response  in  terms
f  overall  opinion  of  the  CLU  was  seen,  which  reinforces
he  participant-reported  satisfaction  with  the  eyelid  gel
reatment.  This  questionnaire  can  therefore  be  strongly  rec-
mmended  for  identifying  new  products  that  may  reduce
nd  manage  DE  symptoms  in  CLU.
The  eyelid  skin  possesses  specific  biochemical  con-
tituents  (collagen  and  elastin)  that  provide  struc-
ural/functional  characteristics  to  defend  the  ocular  globe
hey  cover,  as  well  as  to  regularly  spread  tears  on  the
S  to  keep  it  appropriately  moistened.  Because  of  this,
ny  improvement  of  the  penetration  efficiency  combined
ith  the  release  of  active  products  in  the  skin  can  facili-
ate  the  treatment  of  eyelid  diseases,  as  well  as  favor  the
ntegrity  of  the  structures  of  the  OS.  A  wide  variety  of  in  vivo
echniques  have  been  used  to  evaluate  the  penetration
f  pharmacological  products  into  the  skin,  including  elec-Please  cite  this  article  in  press  as:  Pinazo-Durán  MD
gel  after  repeated  nocturnal  application  in  healthy  co
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ron  paramagnetic  resonance  spectroscopy,  confocal  laser
canning  microscopy,  and  confocal  Raman  microscopy.  Mois-
urizers  topically  applied  affect  skin  barrier  homeostasis.
odén  has  recently  reported  that  some  substances  may  also
w
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enetrate  deeper  into  the  skin  and  induce  changes  in  the
ipid  production.27 In  this  context,  we  speculate  that  the
yelid  gel  can  induce  changes  in  the  palpebral  skin  as  well
s  in  other  components  of  the  OS.
It  is  widely  accepted  that  external/internal  agents  can
dversely  affect  tear  film  stability  and  osmolality  resulting
n  a  variety  of  OS  disorders.  Taking  into  consideration  that
Es  have  an  important,  sometimes  subclinical,  inflammatory
omponent,  the  clinical  probes  are  far  from  complete  for
E  diagnosis.  Normally,  tear  secretion  by  the  main  lacrimal
land  is  approximately  4.5  L.  It  has  been  described  that
 small  amount  of  tears  (2  to  4  L  is  needed  on  the  OS
or  the  appropriate  integrity  of  the  anterior  eye  structures.
FOS.  Quantitative  probes  demonstrated  that  CLU  eyes  had
ignificanly  lower  tear  volume  than  the  NCLU  participants
Schirmer:  8.8  ±  2.6  mm  in  the  CLU,  versus  13.6  ±  2.3  mm
n  the  NCLU).  The  nightly  eyelid  gel  application  in  the
E  induced  a significant  increment  of  the  Schirmer  and
BUT  levels  in  the  CLU  participants.  Average  TBUT  scores
isplayed  no  statistically  significant  differences  between
roups  (4.8  ±  1.6  sec  in  the  CLU  group  versus  6.8  ±  1.5  sec
n  the  NCLU  participants).  However  at  the  end  of  follow-up,
 significant  improvement  respect  to  baseline  values  was
oticed  in  the  probes  from  the  RD  from  the  CLU  participants
Schirmer  test:  13.2  ±  2.2  mm,  p  <  0.05;  TBUT:  7.8  ±  1.2  sec,
 < 0.001).
Scientific  research  has  accumulated  much  immunolog-
cal  evidence  establishing  that  the  DEs  highly  involve  a
mmune  response  and  the  release  of  cytokines/chemokines
nd  its  downstream  effectors.28 The  biochemical  analy-
es  carried  out  in  the  present  work  showed  changes  in
ytokine/chemokine  tear  levels  between  the  two  groups
CLU,  NCLU)  as  well  as  the  two  study  points,  with  a  trend
o  decrease  in  the  RE  exposed  to  the  eyelid  gel  compared
o  the  LE.  However  our  data  did  not  show  statistical  dif-
erences  between  groups  for  the  assayed  panel  of  human
ytokine/chemokine.
The  composition  of  the  eyelid  gel  with  LC-PUFAs  -
ore  specifically  T-DHA-  must  also  be  considered.  Up  to
0  DHA  metabolites  (biologically  active)  have  yet  to  be
dentified.  Among  the  pleiotropic  effects  of  DHA  metabo-
ites,  the  stimulation  of  lipid  catabolism,  the  regulation  of
he  immune  response  by  helping  to  resolve  inflammation,
nd  the  activation  of  wound  healing/tissue  regeneration
ave  to  be  considered.  The  anti-inflammatory  properties
f  3  LC-PUFAs  have  been  extensively  investigated.  Human
icroarray  data  strongly  demonstrate  that  dietary  inter-
ention  with  -3  fatty  acids,  flavonoids,  and  resveratrol
nriches  immune  response  and  disease  pathways,  includ-
ng  their  beneficial  effects  on  DEs.5,15--18 Because  of  this,
e  hypothesize  that  DHA  exerts  an  inhibitory  effect  on  the
ctivation  of  nuclear-  factor,  hindering  the  synthesis  of
nflammatory  cytokines  (IL-6,  TNF-, IL-1) as  well  as  VEGF.
egarding  the  latter,  the  decreased  VEGF  levels  in  tears  from
LU  individuals  at  the  end  of  study  may  reflect  the  amelio-
ation  of  the  subclinical  inflammation  processes  occurring
n  the  OS  as  a  consequence  of  using  the  CL  after  eyelid  gel
pplication.  These  results  need  further  long-lasting  studies,  et  al.  Efficacy  and  safety  study  of  an  eyelid
ntact  lens  users  and  non-users.  J  Optom.  (2020),
ith  larger  sample  sizes  to  assess  the  pathogenic  role  of
EGF  in  DEs.
Globally,  the  results  of  the  present  study  can  be
xplained  as  follows.  (1)Our  participants  were  healthy  CLU
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and  NCLU  individuals,  without  any  previous  diagnosis  of  DEs
or  ocular  pathology.  It  is  plausible  that  this  was  the  reason
why  the  cytokine/chemokine  expression  did  not  significan-
tly  change  between  the  two  study  points.  (2)  The  results
are  positive  in  tolerability  and  appreciation  of  the  eyelid-
gel,  because  the  application  did  not  induce  any  signs  or
symptoms  in  the  OS  or  inflammatory  response  in  tears  from
the  participants  after  2  weeks  of  nightly  application.  (3)
The  time  of  intervention  was  perhaps  too  short  to  detect
changes  in  the  expression  patterns  of  cytokine/chemokine
in  tears.  (4)  The  subjective  data  on  the  cosmetic  effects  of
the  eyelid  gel  application  were  satisfactory  for  the  majority
of  participants.
This  is  the  first  study  demonstrating  that  the  external
application  of  an  eyelid  gel  containing  T-DHA  and  HA  has
a  positive  and  safe  impact  on  the  OS.  An  extensive  search
of  the  scientific  literature  did  not  reveal  studies  similar  to
ours.
Among  the  study  limitations,  as  has  already  been  men-
tion,  the  relatively  small  sample  size  must  be  considered.
Large  cohorts  should  be  analyzed  over  a  longer  duration  to
better  elucidate  the  effects  of  eyelid  gel  administration  on
the  OS  in  CLU  and  NCLU  individuals.  Our  participants  were
also  recruited  on  the  basis  of  not  suffering  DEs.  Finally,  the
2-week  follow-up  may  be  too  short  a  time  to  assess  changes
in  tear  cytokine/chemokine  levels.  It  may  also  have  been
difficult  for  the  participants  to  accurately  discern  between
the  RE  and  LE  subjective  sensations.
To  summarize,  the  results  of  the  present  study  reveal
that  the  application  of  the  eyelid  gel  overnight  is  efficient
and  safe  for  further  use  in  clinical  practice.  These  data  also
suggest  that  a  reduction  of  the  inflammatory  background
present  in  CLU  can  be  counteracted  by  the  tested  eyelid
gel,  registered  as  a  medical  device  formulation,  containing
DHA-TG  and  HA  to  better  manage  OS  disorders  and  eyelid
skin  dryness.
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